Aerie and DSM in Eye Diseases Pact

09:05 EDT 10 Aug 2017 | CHEManager

US clinical stage pharmaceutical company Aerie Pharmaceuticals has entered into a research, development and license agreement with Dutch life sciences group DSM. The agreement includes an option to license DSM’s bio-erodible polymer implant technology for evaluating its application to deliver certain Aerie compounds that are initially focused on retinal diseases.

Original Article: Aerie and DSM in Eye Diseases Pact


More From BioPortfolio on "Aerie and DSM in Eye Diseases Pact"

Quick Search

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...